• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Gain Therapeutics Inc.

    4/29/25 4:07:47 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $GANX alert in real time by email
    DEFA14A 1 ganx-20250425xdefa14a.htm DEFA14A

    ​

    ​

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    ​

    SCHEDULE 14A

    ​

    Proxy Statement Pursuant to Section 14(a) of
    the Securities Exchange Act of 1934

    (Amendment No.__)

    ​

    ​

    ​

    Filed by the Registrant

    ☒

    Filed by a party other than the Registrant

    ☐

    ​

    Check the appropriate box:

    ​

    ​

    ☐

    Preliminary Proxy Statement

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

    ☐

    Definitive Proxy Statement

    ☒

    Definitive Additional Materials

    ☐

    Soliciting Material under § 240.14a-12

    ​

    GAIN THERAPEUTICS, INC.

    (Name of Registrant as Specified In Its Charter)

    ​

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

    ​

    ​

    ☒

    No fee required

    ☐

    Fee paid previously with preliminary materials

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

    ​

    ​

    00


    GRAPHIC

    GAIN THERAPEUTICS, INC. Annual Meeting of Stockholders June 24, 2025 at 8:30 a.m. EDT at the offices of Lowenstein Sandler LLP, 1251 Avenue of the Americas, Floor 17, New York, New York 10020. For a convenient way to view proxy materials, VOTE, and obtain directions to attend the meeting go to: https://web.viewproxy.com/ganx/2025 To vote your proxy while visiting this site, you will need the 11 digit control number in the box on this page. This communication presents only an overview of the more complete proxy materials that are available to you on the internet. This is not a Proxy Card. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the Internet. If you want to receive a paper or Email copy of the proxy material, you must request one, there is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before June 13, 2025. PLEASE VOTE NOW! SEE REVERSE FOR FULL AGENDA Meeting Materials: Notice of Meeting and Proxy Statement & Annual Report or Form 10-K. Important Notice Regarding the Availability of Proxy Materials for the Stockholders Meeting To Be Held On June 24, 2025. For Stockholders of record as of April 25, 2025. Internet: https://web.viewproxy.com/ganx/2025 Phone: 1-877-777-2857 Email: [email protected] * If requesting material by Email, please send a blank Email with the 11 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your Email requesting material. Scan QR Code for Digital Voting ORDER PAPER MATERIALS, USE ONE OF THE FOLLOWING METHODS. CONTROL NUMBER GAIN THERAPEUTICS, INC.

    GRAPHIC

    Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: “FOR” the election of each named nominee for Director and “FOR” Proposals 2, 3 and 4. Proposal 1: Election of Directors 01 Gene Mack 02 Khalid Islam, Ph.D. 03 Dov Goldstein, M.D. 04 Hans Peter Hasler 05 Gwen Melincoff 06 Claude Nicaise, M.D. 07 Eric I. Richman 08 Jeffrey Riley Proposal 2: To ratify the selection by the Audit Committee of the Board of Directors of Ernst & Young AG as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. Proposal 3: To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to increase the Company’s authorized shares of common stock from 50,000,000 to 100,000,000. Proposal 4: To approve the adjournment of the Annual Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of Proposal 3. NOTE: Your proxy holder will also vote in their discretion on any other business as may properly come before the meeting or any adjournment or postponement thereof (including, without limitation, with discretionary authority under Proposal 1 to vote for a substitute nominee if any nominee is unable to serve or for good cause will not serve). GAIN THERAPEUTICS, INC.

    Get the next $GANX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GANX

    DatePrice TargetRatingAnalyst
    3/7/2025$12.00Sector Outperform
    Scotiabank
    12/6/2024$7.00Buy
    ROTH MKM
    8/14/2024$8.00Outperform
    Oppenheimer
    11/3/2021$21.00Buy
    B. Riley Securities
    More analyst ratings

    $GANX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gain Therapeutics Announces Announces Conference Participation During J.P. Morgan Healthcare Conference Week

    BETHESDA, Md., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced its attendance at conferences during the week of the 44th Annual J.P. Morgan Healthcare Conference ("JPM week") including at the Sachs Neuroscience Innovation Forum, the Demy-Colton/Informa Biotech Showcase™, and the LifeSci Advisors Corporate Access Event. Information on all events is below. The 9th Annual Sachs Neuroscience Innovation ForumDate: January 11, 2026Format: Presentation and one-on-one meetings with managemen

    1/7/26 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Highlights Biomarker Evidence Supporting Disease-Modifying Potential of GT-02287

    BETHESDA, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today provided additional biomarker and clinical data from the Phase 1b clinical study of GT-02287 in people with Parkinson's disease (PD) with or without a GBA1 mutation that further supports the disease-modifying potential of GT-02287. In participants with elevated baseline levels of glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF) at baseline, GluSph decreased by an average of 81% after 90 days of treatment with GT-02287. Elev

    1/6/26 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics to Host Virtual KOL Event on GT-02287 for Parkinson's Disease

    BETHESDA, Md., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that it will host a virtual key opinion leader (KOL) event, "Understanding GCase Substrates in Parkinson's Disease: Perspectives on Biomarkers and Disease Modification, Contextualizing emerging biomarker data from the Phase 1b clinical study of GT-02287". Featured Key Opinion Leaders (KOLs) will be Roy Alcalay, M.D., M.Sc., Chief of Movement Disorders Division, Tel Aviv Sourasky Medical Center, Professor of Neurology, Tel A

    12/18/25 4:05:00 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CFO and Interim CEO Mack Gene bought $14,544 worth of shares (14,400 units at $1.01) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:31 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Executive Chairman Islam Khalid bought $49,940 worth of shares (50,000 units at $1.00) (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    8/12/24 5:23:30 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Richman Eric I bought $20,670 worth of shares (17,000 units at $1.22), increasing direct ownership by 6% to 289,629 units (SEC Form 4)

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    7/1/24 5:00:27 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Islam Khalid

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:23 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Richman Eric I

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:19 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Nicaise Claude

    4 - Gain Therapeutics, Inc. (0001819411) (Issuer)

    6/25/25 5:30:22 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    SEC Filings

    View All

    Gain Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

    2/3/26 4:25:21 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Inc. filed SEC Form 8-K: Other Events

    8-K - Gain Therapeutics, Inc. (0001819411) (Filer)

    12/18/25 9:00:45 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Gain Therapeutics Inc.

    S-8 - Gain Therapeutics, Inc. (0001819411) (Filer)

    12/3/25 4:02:28 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Scotiabank initiated coverage on Gain Therapeutics with a new price target

    Scotiabank initiated coverage of Gain Therapeutics with a rating of Sector Outperform and set a new price target of $12.00

    3/7/25 8:20:06 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ROTH MKM initiated coverage on Gain Therapeutics with a new price target

    ROTH MKM initiated coverage of Gain Therapeutics with a rating of Buy and set a new price target of $7.00

    12/6/24 7:48:38 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Oppenheimer resumed coverage on Gain Therapeutics with a new price target

    Oppenheimer resumed coverage of Gain Therapeutics with a rating of Outperform and set a new price target of $8.00

    8/14/24 7:36:01 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Financials

    Live finance-specific insights

    View All

    Gain Therapeutics Reports Financial Results for First Quarter 2025 and Provides Corporate Update

    BETHESDA, Md., May 14, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the quarter ended March 31, 2025, and provided a corporate update. "The first quarter of 2025 marked yet another exciting milestone for Gain with the first administration of GT-02287, our lead drug candidate in development for the treatment of Parkinson's disease (PD) with or without a GBA1 mutation, to participants with Parkinson's disease in our ongoing Phase 1b study which began enrollment in early M

    5/14/25 7:30:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for the Fourth Quarter and Year End 2024 and Provides Corporate Update

    BETHESDA, Md., March 27, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reported financial results for the fourth quarter and year ended December 31, 2024, and provided a corporate update. "2024 was a year of significant progress for Gain, as we made important advancements related to both the scientific understanding and clinical development of our lead candidate GT-02287, in development for the treatment of Parkinson's disease with or without GBA1 mutation," said Gene Mack, President and CEO

    3/27/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Reports Financial Results for Third Quarter 2024 and Provides Corporate Update

    BETHESDA, Md., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today reports financial results for the quarter ended September 30, 2024, and provides a corporate update. "The third quarter of 2024 marked substantial progress for Gain and the development of GT-02287, our lead candidate for the treatment of Parkinson's disease in patients with or without the GBA1 mutation. Data from our Phase 1 study for GT-02287 presented recently at both the International Congress of Parkinson's Disease and Movement

    11/14/24 4:05:00 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Leadership Updates

    Live Leadership Updates

    View All

    Gain Therapeutics Appoints Gene Mack as Chief Executive Officer and Director

    Gene Mack Has Served As CFO Since April 2024 And Interim CEO Since June 2024 Gianluca Fuggetta Will Assume The Role Of Senior Vice President, Finance BETHESDA, Md., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced that Gene Mack, who has served as the Company's Chief Financial Officer since April 2024 and interim Chief Executive Officer since June 2024, has been appointed President and Chief Executive Officer, effective January 6, 2025. Mr. Mack has also been appointed as a me

    1/7/25 7:00:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO

    Mr. Mack is the Company's Current CFO Khalid Islam, PhD, Founder and Chairman of the Board, to serve as Executive Chairman BETHESDA, Md., June 27, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces that Matthias Alder has departed the Company in order to pursue other opportunities. Upon Mr. Alder's departure, the Company appointed Gene Mack, the Company's current Chief Financial Officer, as interim Chief Executive Officer, effective June 25, 2024. Mr. Mack will retain his role as Chief Finan

    6/27/24 4:08:08 PM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Gain Therapeutics Bolsters Management Team with the Appointment of Gene Mack as Chief Financial Officer

    BETHESDA, Md., April 08, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ:GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announces the appointment of Gene Mack, MBA as its chief financial officer, effective as of April 8, 2024. "We are thrilled to welcome Gene as our new CFO," commented Gain CEO Matthias Alder. "His experience as an operational CFO with a track record of successful financing, M&A and other strategic transactions combined with his scientific background and career as an equity research analyst ideally complement our executive man

    4/8/24 9:25:00 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $GANX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Gain Therapeutics Inc.

    SC 13G/A - Gain Therapeutics, Inc. (0001819411) (Subject)

    3/29/21 11:59:04 AM ET
    $GANX
    Biotechnology: Pharmaceutical Preparations
    Health Care